Search results
Results from the WOW.Com Content Network
Renal glycosuria is a rare condition in which the simple sugar glucose is excreted in the urine [1] despite normal or low blood glucose levels. With normal kidney (renal) function, glucose is excreted in the urine only when there are abnormally elevated levels of glucose in the blood.
This point is called the renal threshold for glucose (RTG). [5] Some people, especially children and pregnant women, may have a low RTG (less than ~7 mmol/L [5] glucose in blood to have glucosuria). If the RTG is so low that even normal blood glucose levels produce the condition, it is referred to as renal glycosuria.
Renal glucose reabsorption is the part of kidney (renal) physiology that deals with the retrieval of filtered glucose, preventing it from disappearing from the body through the urine. If glucose is not reabsorbed by the kidney, it appears in the urine, in a condition known as glycosuria. This is associated with diabetes mellitus. [1]
Mutations in this gene are also associated with renal glycosuria. [14]Sodium-glucose cotransporter-2 (SGLT2) inhibitors were associated with significant long-term reductions in mortality risk for patients with pulmonary arterial hypertension (PAH), according to an observational cohort study. [15]
A drug treatment for type 2 diabetes; belongs to a class of drugs called biguanides. First-line pharmacotherapy for type 2 diabetes mellitus. Mg/dL Milligrams per deciliter. How much glucose (sugar) is in a specific amount of blood. In self-monitoring of blood glucose, test results are given as the amount of glucose in milligrams per deciliter ...
Fanconi syndrome or Fanconi's syndrome (English: / f ɑː n ˈ k oʊ n i /, / f æ n-/) is a syndrome of inadequate reabsorption in the proximal renal tubules [1] of the kidney.The syndrome can be caused by various underlying congenital or acquired diseases, by toxicity (for example, from toxic heavy metals), or by adverse drug reactions. [2]
Sotagliflozin (Inpefa) is a dual SGLT1/SGLT2 inhibitor approved by the US Food and Drug Administration (FDA) in May 2023, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, chronic kidney disease, and other cardiovascular risk factors.
The NSAID diclofenac has an antiuricosuric action, which may be partly responsible for the extraordinary toxicity of this drug in vultures. [6] Pyrazinamide, a drug indicated only for treatment of tuberculosis, is a potent antiuricosuric [7] and, as a consequence, has an off-label use in the diagnosis of causes of abnormal uric acid clearance. [8]